[1]
|
Chen, W., Liang, J.L., Zhou, K., Zeng, Q.L., Ye, J.W. and Huang, M.J. (2020) Effect of CIP2A and Its Mechanism of Action in the Malignant Biological Behavior of Colorectal Cancer. Cell Communication and Signaling, 18, 67.
https://doi.org/10.1186/s12964-020-00545-6
|
[2]
|
Ma, L., Wen, Z.S., Liu, Z., Hu, Z. and Zhou, G.B. (2011) Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer. PLoS ONE, 6, e20159. https://doi.org/10.1371/journal.pone.0020159
|
[3]
|
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P.M., Rao, Z., Xu, W. and Westermarck, J. (2017) Oncoprotein CIP2A Is Stabilized via Interaction with Tumor Suppressor PP2A/B56. EMBO Reports, 18, 437-450. https://doi.org/10.15252/embr.201642788
|
[4]
|
Denk, S., Schmidt, S., Schurr, Y., Schwarz, G., Schote, F., Diefenbacher, M., Armendariz, C., Dejure, F., Eilers, M. and Wiegering, A. (2020) CIP2A Regulates MYC Translation (via Its 5’UTR) in Colorectal Cancer. International Journal of Colorectal Disease, 36, 911-918. https://doi.org/10.1007/s00384-020-03772-y
|
[5]
|
Austin, J.A., Jenkins, R.E., Austin, G.M., Glenn, M.A. and Clark, R.E. (2019) Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Modifies Energy Metabolism via 5’AMP-Activated Protein Kinase Signalling in Malignant Cells. Biochemical Journal, 476, BCJ20190121. https://doi.org/10.1042/BCJ20190121
|
[6]
|
Khan, M.M., Ullah, U., Khan, M.H., Kong, L., Moulder, R., Valikangas, T., Bhosale, S.D., Komsi, E., Rasool, O., Chen, Z., Elo, L.L., Westermarck, J. and Lahesmaa, R. (2020) CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling. iScience, 23, Article ID: 100947. https://doi.org/10.1016/j.isci.2020.100947
|
[7]
|
Tian, Y., Chen, H., Qiao, L., Zhang, W., Zheng, J., Zhao, W., Chen, J.J. and Zhang, W. (2018) CIP2A Facilitates the G1/S Cell Cycle Transition via B-Myb in Human Papillomavirus 16 Oncoprotein E6-Expressing Cells. Journal of Cellular and Molecular Medicine, 22, 4150-4160. https://doi.org/10.1111/jcmm.13693
|
[8]
|
Clark, R.E., Basabrain, A.A., Austin, G.M., Holcroft, A.K., Loaiza, S., Apperley, J.F., Law, C., Scott, L., Parry, A.D., Bonnett, L. and Lucas, C.M. (2021) Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers (Basel), 13, 2155.
https://doi.org/10.3390/cancers13092155
|
[9]
|
Makela, E., Pavic, K., Varila, T., Salmenniemi, U., Loyttyniemi, E., Nagelli, S.G., Ammunet, T., Kahari, V.M., Clark, R.E., Elo, L.L., Bachanaboyina, V.K., Lucas, C.M., Itala-Remes, M. and Westermarck, J. (2021) Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clinical Cancer Research, 27, 2848-2860. https://doi.org/10.1101/2020.08.24.264606
|
[10]
|
Aslan, F., Guney, G., Avcikurt, A.S., Taskin, M.I. and Akgun, G.A. (2020) Relationship between CIP2A and Endometrium Cancer. Journal of College of Physicians and Surgeons Pakistan, 30, 373-378.
https://doi.org/10.29271/jcpsp.2020.04.373
|
[11]
|
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J. and Zhou, Y. (2020) Micropeptide CIP2A-BP Encoded by LINC00665 Inhibits Triple-Negative Breast Cancer Progression. EMBO Journal, 39, e102190. https://doi.org/10.15252/embj.2019102190
|
[12]
|
刘喜婷, 杨磊, 马琴, 顾峰, 吴玉强. Wnt信号通路介导CIP2A沉默诱导肺癌细胞凋亡[J]. 中国老年学杂志, 2019, 39(12): 2982-2986.
|
[13]
|
Saafan, H., Alahdab, A., Michelet, R., Gohlke, L. and Ritter, C.A. (2021) Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line. Cells, 10, 716. https://doi.org/10.3390/cells10040716
|
[14]
|
Nishio, E., Hayashi, T., Akaza, M., Hisatomi, Y., Hikichi, M., Fujii, T., Utsumi, T., Harada, N. and Shimono, Y. (2020) Upregulation of CIP2A in Estrogen Depletion-Resistant Breast Cancer Cells Treated with Low-Dose Everolimus. FEBS Open Bio, 10, 2072-2080. https://doi.org/10.1002/2211-5463.12956
|
[15]
|
Zhu, Z. and Wei, Z. (2021) CIP2A Silencing Alleviates Doxorubicin Resistance in MCF7/ADR Cells through Activating PP2A and Autophagy. Clinical and Translational Oncology, 23, 1542-1548.
https://doi.org/10.1007/s12094-021-02616-7
|
[16]
|
Kim, S.H., Lee, W.H., Seong, D., An, J.H., Je, H.U., Nam, H.Y., Kim, S.Y., Kim, S.W. and Han, M.W. (2019) The Role of CIP2A as a Therapeutic Target of Rapamycin in Radioresistant Head and Neck Cancer with TP53 Mutation. Head Neck, 41, 3362-3371. https://doi.org/10.1002/hed.25868
|
[17]
|
Feng, F., Cheng, P., Wang, C., Wang, Y. and Wang, W. (2019) Polyphyllin I and VII Potentiate the Chemosensitivity of A549/DDP Cells to Cisplatin by Enhancing Apoptosis, Reversing EMT and Suppressing the CIP2A/AKT/mTOR Signaling Axis. Oncology Letters, 18, 5428-5436. https://doi.org/10.3892/ol.2019.10895
|
[18]
|
Shen, F., Chen, Y., Chen, L., Qin, J. and Xu, J. (2019) Amentoflavone Promotes Apoptosis in Non-Small-Cell Lung Cancer by Modulating Cancerous Inhibitor of PP2A. The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology, 302, 2201-2210. https://doi.org/10.1002/ar.24229
|
[19]
|
Feng, F.-F., Cheng, P., Sun, C., Wang, H. and Wang, W. (2019) Inhibitory Effects of Polyphyllins I and VII on Human Cisplatin-Resistant NSCLC via p53 Upregulation and CIP2A/AKT/mTOR Signaling Axis Inhibition. Chinese Journal of Natural Medicines, 17, 768-777. https://doi.org/10.1016/S1875-5364(19)30093-7
|
[20]
|
张洪兰, 陈昊, 张春芳, 张昶, 齐冬雪, 李伟, 刘新丽, 刘华. 贲门胃底癌中CIP2A mRNA表达与HER-2基因的扩增及其意义[J]. 实用医学杂志, 2018, 34(24): 4032-4036.
|
[21]
|
Lin, X., Gao, M., Zhang, A., Tong, J., Zhang, X., Su, Q., Yang, Z., Gao, H. and Jiang, G. (2019) FL118 Inhibits Viability and Induces Apoptosis of Colorectal Cancer Cells via Inactivating the CIP2A/PP2A Axis. Life Sciences, 239, Article ID: 117074. https://doi.org/10.1016/j.lfs.2019.117074
|
[22]
|
杨雪, 张靖, 韩少山, 陶杰, 孙昊, 刘青光. 抑制CIP2A表达对肝癌细胞HepG2生物学特性影响的体内外研究[J]. 西安交通大学学报(医学版), 2019, 40(3): 362-367.
|
[23]
|
庞荣, 周全, 李茂. 异丙酚通过调节CIP2A-PP2A通路抑制HepG2细胞增殖[J]. 宁夏医科大学学报, 2020, 42(12): 1207-1211.
|
[24]
|
Zhang, S. and Wang, K. (2020) miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion. OncoTargets and Therapy, 13, 4063-4074. https://doi.org/10.2147/OTT.S248116
|
[25]
|
Liu, C.Y., Huang, T.T., Chen, Y.T., Chen, J.L., Chu, P.Y., Huang, C.T., Wang, W.L., Lau, K.Y., Dai, M.S., Shiau, C.W. and Tseng, L.M. (2019) Targeting SET to Restore PP2A Activity Disrupts an Oncogenic CIP2A-Feedforward Loop and Impairs Triple Negative Breast Cancer Progression. EBioMedicine, 40, 263-275.
https://doi.org/10.1016/j.ebiom.2018.12.032
|
[26]
|
Gao, D., Nyalali, A.M.K., Hou, Y., Xu, Y., Zhou, J., Zhao, W., Huang, B. and Li, F. (2021) 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis. Journal of Molecular Neuroscience, 71, 1703-1713. https://doi.org/10.1007/s12031-020-01773-8
|
[27]
|
Gao, H., Li, Y., Lin, T., Cheng, Y. and Ma, Y. (2020) Downregulation of CIP2A Inhibits Cancer Cell Proliferation and Vascularization in Renal Clear Cell Carcinoma. Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 164, 196-202. https://doi.org/10.5507/bp.2019.031
|
[28]
|
Zhang, Y., Fang, L., Zang, Y., Ren, J. and Xu, Z. (2018) CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma. Journal of Cancer, 9, 4029-4038. https://doi.org/10.7150/jca.25005
|
[29]
|
Ma, W., Xiang, Y., Yang, R., Zhang, T., Xu, J., Wu, Y., Liu, X., Xiang, K., Zhao, H., Liu, Y. and Si, Y. (2019) Cucurbitacin B Induces Inhibitory Effects via the CIP2A/PP2A/C-KIT Signaling Axis in t(8;21) Acute Myeloid Leukemia. Journal of Pharmacological Sciences, 139, 304-310. https://doi.org/10.1016/j.jphs.2018.12.010
|